版本:
中国

BRIEF-Gilead submits NDA for fixed-dose combination for HIV treatment

June 12 Gilead Sciences Inc:

* Gilead submits new drug application to U.S. Food and drug administration for fixed-dose combination of bictegravir, emtricitabine and tenofovir alafenamide for HIV treatment

* Investigational single tablet regimen may have potential to advance triple-therapy hiv treatment for a broad range of patients

* Plans to submit a marketing authorization application for bic/ftc/taf in european union in Q3 of 2017

* NDA for bic/ftc/taf is supported by data from four phase 3 studies in which regimen met its primary objective of non-inferiority Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐